Evil, Mels and all their likers -
Two in three of
Evil, Mels and all their likers -
Two in three of severe/critical patients would live if given standard of care.
Please, that factor is the difference between relative and absolute risk reduction and the point of calculating number needed to treat. Are you really still confused about that?
You can't calculate how many lives a given number of doses will save without knowing the distinction.
And my saying we already have enough to make a material difference, but not enough to blanket the world, is hardly cold water.
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
No Smooth Sailing in HBX's Waters Tell you what, HBX Group's third-quarter update feels like a mixed bag of tricks. They’ve pulled off a decent 12% boost in Total Transaction Value (TTV), hitting €2.4 billion. Now, that’s an eyebrow-raiser in this market, especially when leisure travel's still rebounding. But, and there’s always a but, revenue's slid 3%...
Continue Reading
Beam Global Announces Strong Second Quarter Results Beam Global, a renowned provider of sustainable infrastructure solutions focused on electrification and energy security, has recently unveiled impressive financial results for the second quarter. This announcement reinforces Beam's commitment to growth and innovation within the clean energy sector. Financial Highlights...
Continue Reading
Dispelix and RTX's Collins Aerospace Join Forces Dispelix, a leader in augmented reality (AR) waveguide display technology, and Collins Aerospace, part of RTX, have embarked on a transformative partnership. This collaboration is centered around a long-term supply agreement aimed at integrating Dispelix's cutting-edge AR waveguide displays into Collins Aerospace's...
Continue Reading
Dundee Precious Metals Provides Update on the ?oka Rakita Project Today, Dundee Precious Metals Inc. (TSX: DPM) announced important updates regarding the ?oka Rakita project. The company's latest report confirms that the pre-feasibility study (PFS) is set for completion in early 2025, indicating a positive trajectory for the project's growth. Additionally, new assay...
Continue Reading
Citi Adjusts Cadence BanCorp Price Target Citi has recently updated its outlook for Cadence BanCorp (NYSE: CADE), maintaining a Neutral rating while elevating the price target to $37 from $35. This revision comes as analysts foresee continued net interest margin (NIM) expansion paired with prudent cost management strategies that are expected to benefit the bank in the...
Continue Reading
